Clarus Therapeutics Announces Completion of $8 Million Series C Financing Round
11/27/2007 10:48:23 AM
NORTHBROOK, Ill.--(BUSINESS WIRE)--Clarus Therapeutics, Inc., a private firm focused on the development of an oral testosterone replacement product, today announced the close of an $8 million Series C financing. H.I.G. Ventures led the round and was joined by Thomas, McNerney & Partners – the sole institutional investor in the Series A and B rounds. To date, Clarus has secured venture funding commitments totaling $15 million. In conjunction with the Series C financing, Bruce Robertson, Ph.D. and Michael Wasserman, Ph.D. of H.I.G. Ventures will join Alex Zisson and James Thomas from Thomas, McNerney & Partners and President and CEO Robert Dudley, Ph.D. on Clarus’s board of directors.